Arcus Biosciences (RCUS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting called to order at 8:30 A.M. with board members and executive team present.
Stockholders welcomed and informed of procedures for submitting questions.
Notice of meeting and stockholder list confirmed as distributed and available.
Board and executive committee updates
Attendance included all board members, key executives, and company auditors.
Shareholder proposals
Three proposals presented: election of directors, ratification of auditors, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Arcus Biosciences
- Pivotal ARC-20 data and phase III trials aim to establish casdatifan as a market leader in RCC.RCUS
Morgan Stanley 24th Annual Global Healthcare Conference - Upcoming data for casdatifan may establish new benchmarks in kidney cancer treatment efficacy.RCUS12th Annual Cantor Fitzgerald Global Healthcare Conference
- Major October data update for casdatifan aims to boost confidence in pivotal renal cancer trials.RCUSCitigroup’s Biopharma Back to School Summit 2026
- Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential.RCUSCorporate presentation
- Casdatifan advanced in RCC, new partnerships secured, and $775M cash runway projected into 2028.RCUSQ2 2026
- Castatinopathy demonstrates superior efficacy in RCC trials, targeting major market growth.RCUSH.C. Wainwright 27th Annual Global Investment Conference
- Casdatifan and quemliclustat drive strong clinical and market prospects with pivotal data ahead.RCUSGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Q1 2025 net loss was $112M on $28M revenue; cash reserves strong at $1B.RCUSQ1 2025
- Casdatifan outperforms belzutifan in ccRCC, with strong efficacy, safety, and major market potential.RCUSStatus Update